The research will investigate the mechanisms by which our brains are able to listen selectively to sounds of interest in competing background noise. This will be investigated in normal hearing subjects, those with partial deafness and in profoundly deaf patients who use a cochlear implant. If deaf patients can learn to use cues to enhance detection of sounds of interest this could have an impact on the effectiveness of hearing aids and cochlear implants in noisy listening situations
Epilepsy is a debilitating neurological disorder characterised by spontaneous seizures. For a third of epilepsy patients, drugs cannot prevent epileptic seizures from occurring without causing severe side effects. Therefore alternative treatments are needed. This work will develop epileptic seizure warning methods. This will alleviate the stress of randomly occurring seizures by giving patients the chance to move to safety before a seizure occurs, therefore enhancing their quality of life.
Next Generation Brain-Machine Interface: Minimally-Invasive Endovascular Stent-Electrode Array For Robotic Limb Control
Funder
National Health and Medical Research Council
Funding Amount
$1,735,574.00
Summary
Persons affected by quadriplegia and hemiplegia from stroke and spinal cord injury have few treatment options. Brain Machine Interfaces (BMIs) reconnect brain to a prosthetic limb, bypassing damaged nervous system. Our group has developed a BMI that can be implanted minimally-invasively, inside a blood vessel within the brain. We propose to evaluate this device in animal studies, and continue on to a human clinical trial pilot study. The aim is to restore mechanical control over the physical env ....Persons affected by quadriplegia and hemiplegia from stroke and spinal cord injury have few treatment options. Brain Machine Interfaces (BMIs) reconnect brain to a prosthetic limb, bypassing damaged nervous system. Our group has developed a BMI that can be implanted minimally-invasively, inside a blood vessel within the brain. We propose to evaluate this device in animal studies, and continue on to a human clinical trial pilot study. The aim is to restore mechanical control over the physical environment for a paralysed patient.Read moreRead less
Quantifying The Ventilatory Control Contribution To Obstructive Sleep Apnoea Using Clinical Polysomnography
Funder
National Health and Medical Research Council
Funding Amount
$196,995.00
Summary
Obstructive sleep apnoea is a highly prevalent condition with limited treatment options. New research shows that many patients have sleep apnoea because of a hypersensitive control of breathing (instability). Yet there is no way to measure instability and target it clinically. We aim to refine and apply a powerful new method to measuring breathing instability using a conventional sleep study, to allow treatments for sleep apnoea to be targeted at those patients who will respond most effectively.
Cardiovascular Effects Of Enhanced Leptin Signalling
Funder
National Health and Medical Research Council
Funding Amount
$1,200,972.00
Summary
Leptin treatment causes weight loss, but leptin also increases blood pressure. We wish to determine if increasing leptin signalling, by modifying signal transduction pathways within leptin sensitive cells in the brain, can reduce weight without increasing blood pressure.
Regulation Of Ca2+/calmodulin Dependent Protein Kinase Kinase-2 By Phosphorylation
Funder
National Health and Medical Research Council
Funding Amount
$570,334.00
Summary
This project will study the regulation of an enzyme called CaMKK2, which plays a pivotal role in controlling a number of important biological functions including brain development, regulation of appetite, energy metabolism and blood pressure. Understanding how this enzyme is regulated may open new avenues for treating Type 2 diabetes, obesity, and cardiovascular disease.
Insulin triggers glucose uptake into fat and muscle tissue, a process that is defective in type 2 diabetes. Insulin does this by triggering a complex cascade of actions once it binds to muscle and fat cells. We will analyse the function of a crucial protein within this cascade. This protein is mutated in humans with severe insulin resistance and our proposed project will dissect how this protein works potentially providing a novel drug target to treat diabetes.
Cells are building blocks of living things and require signalling pathways to communicate their functions. We discovered a new signalling pathway in flies that remarkably exists in yeast and plants to more complex organisms like mice and man. We will study this new signalling pathway in flies to find out how and why it communicates in cells. As flies and humans share similar genes, our studies will inform how this previously unknown signalling pathway functions from simple to complex organisms
The Targeting Of Flt3, C-Kit And Src As Therapies For C-Cbl-associated Myeloid Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$535,416.00
Summary
Most leukaemias are incurable so it is important to find new treatments. For this to occur it is essential that the mutated genes causing leukaemia are identified. We have generated a mouse with a mutation in a gene, c-Cbl, that promotes the activation of a number of proteins involved in leukaemia development. By treating c-Cbl mutant mice with drugs that target these proteins we intend to identify the most effective treatments for human leukaemias associated with c-Cbl mutations.
Studies Of Cullin 5 Deficiency For Novel Insights Into SOCS Redundancy And Specificity
Funder
National Health and Medical Research Council
Funding Amount
$658,571.00
Summary
Cytokines are hormones that regulate blood cell production and function. The research proposed in this application focuses on the biological roles and biochemical mechanisms of action of an important family of proteins that control the actions of cytokines, thereby allowing their beneficial effects in coordinating oxygen transport, blood clotting and responses to infection, while preventing the harmful effects of excess responses, such as myeloproliferative diseases or autoimmunity.